Dyne Therapeutics is on track to seek U.S. accelerated approval for its Duchenne muscular dystrophy drug z-rostudirsen this quarter after new data showed it restored dystrophin protein to nearly 10% of normal levels, a significant step for the muscle-wasting disease treatment.
“Following positive topline data late last year, we continue to ramp up activities to support a potential launch of z-rostudirsen in DMD in the first quarter of 2027,” John Cox, president and chief executive officer of Dyne, said in a statement. “We are grateful to the FDA for a collaborative pre-BLA meeting, where we aligned on the contents of our planned BLA submission.”
The clinical-stage company reported a net loss of $120.9 million, or $0.73 per share, for the first quarter of 2026, compared to a loss of $115.4 million a year prior. Dyne ended the quarter with $972.2 million in cash and marketable securities, which it expects will fund operations into early 2028. Research and development expenses dipped to $100.9 million, while administrative costs rose 53 percent to $24.4 million in preparation for a potential launch.
The planned regulatory submission and potential 2027 launch for z-rostudirsen create a clear path forward for Dyne’s lead asset. With a cash runway extending to the anticipated launch of its second candidate in 2028, the company is positioned to transition from a development-stage biotech to a commercial entity, contingent on FDA approvals.
Z-rostudirsen Nears Finish Line in DMD
Dyne’s confidence follows a positive pre-Biologics License Application meeting with the U.S. Food and Drug Administration. The company plans to submit for Accelerated Approval for z-rostudirsen in patients with DMD amenable to exon 51 skipping in the second quarter of 2026.
The submission will be supported by long-term data from the Phase 1/2 DELIVER trial. In four participants dosed for at least one year, unadjusted dystrophin production reached an average of 9.48% of normal levels, a substantial increase from 0.52% at baseline. Dystrophin is the key protein that is missing in patients with DMD, and its restoration is a primary goal of treatment. Dyne plans to initiate a global confirmatory Phase 3 trial in the second quarter of 2026 after aligning with the FDA on its design.
DM1 Program Builds Momentum
Dyne is also advancing its second lead candidate, z-basivarsen, for myotonic dystrophy type 1 (DM1). The company has hit its enrollment target of 60 participants in the registrational cohort of the ACHIEVE trial and expects to exceed that number when enrollment closes this quarter.
Data from this cohort, expected in the first quarter of 2027, will form the basis of a potential BLA submission for Accelerated Approval in early Q3 2027. This timeline targets a potential U.S. launch in the first quarter of 2028. In parallel, Dyne initiated the global confirmatory Phase 3 HARMONIA trial for z-basivarsen in March 2026.
This article is for informational purposes only and does not constitute investment advice.
